
CoroCompass CV Risk Prevention
ASCVD Risk and Treatment Tool
0 ratings
$0.99 Free
In-App Purchases
Lowest price: $0.99 7 months ago (-%)
↓
Price history
About
CoroCompass is the essential digital assistant for cardiology prevention, designed for clinicians helping patients navigate risk stratification and lipid management.
Key Features:
• Advanced Risk Stratification: Calculate 10-year ASCVD risk, augmented with integrated guideline-based "risk enhancers".
• Coronary Calcium (CAC) Scoring: Input Agatston scores and demographics to instantly visualize MESA percentiles and risk categories.
• Lipid Management: Built-in Friedewald LDL calculator and guideline-directed goal setting.
• Clinical Decision Support: Generate instant, text-based clinical summaries with specific recommendations for statin therapy and aspirin therapy based on the latest ACC/AHA prevention and cholesterol guidelines.
• Reference Library: Quick access to statin therapy intensity tables and key guideline summaries and hyperlinks.
Designed for Speed and Privacy:
• No login required.
• All calculations happen locally on your device (no need for internet connection).
• No patient data is ever stored or transmitted.
Streamline your primary prevention workflow with this suite of guideline-based tools!
IMPORTANT MEDICAL DISCLAIMER: This app is designed for educational and clinical decision support purposes only. It is not intended to provide a medical diagnosis or replace professional medical advice, diagnosis, or treatment. The calculations and recommendations provided are based on established clinical guidelines but should not be used as the sole basis for patient care. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this application.
Show more
What's New in CoroCompass CV Risk Prevention
1.4
March 27, 2026
CoroCompass has been updated to incorporate the latest clinical evidence and guideline-directed medical therapy. • 2026 Dyslipidemia Guidelines: Full integration of the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Access updated risk assessment tools and evidence-based statin therapy recommendations. • Improved Compliance: We have updated our User Agreement to better reflect our commitment to data privacy and professional use. • Bug Fixes: Performance improvements and minor UI refinements to ensure a smoother clinical experience.
More3
In-App Purchases
$2.99
100 Assessment Credits
Generate 100 comprehensive reports.







